Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

From Wikipedia, the free encyclopedia

NESS-0327
Identifiers
CAS Number
PubChem CID
Chemical and physical data
FormulaC24H23Cl3N4O
Molar mass489.83 g·mol−1
3D model (JSmol)
  • Clc3cc(Cl)ccc3-n4c2-c1ccc(Cl)cc1CCCc2c(n4)C(=O)NN5CCCCC5
  • InChI=1S/C24H23Cl3N4O/c25-16-7-9-18-15(13-16)5-4-6-19-22(24(32)29-30-11-2-1-3-12-30)28-31(23(18)19)21-10-8-17(26)14-20(21)27/h7-10,13-14H,1-6,11-12H2,(H,29,32) ☒N
  • Key:NCXBPZJQQSNIRA-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

NESS-0327 is a drug used in scientific research which acts as an extremely potent and selective antagonist of the cannabinoid receptor CB1. It is much more potent an antagonist, and more selective for the CB1 receptor over CB2, than the more commonly used ligand rimonabant, with a Ki at CB1 of 350fM (i.e. 0.00035nM) and a selectivity of over 60,000x for CB1 over CB2.[1] Independently, two other groups have described only modest nanomolar CB1 affinity for this compound (125nM[2] and 18.4nM[3]). Also unlike rimonabant, NESS-0327 does not appear to act as an inverse agonist at higher doses, instead being a purely neutral antagonist which blocks the CB1 receptor but does not produce any physiological effect of its own.[4]

See also

References

  1. ^ Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, et al. (July 2003). "Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 363–70. doi:10.1124/jpet.103.049924. PMID 12663689. S2CID 32018707.
  2. ^ Stoit AR, Lange JH, Hartog AP, Ronken E, Tipker K, Stuivenberg HH, et al. (August 2002). "Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists". Chemical & Pharmaceutical Bulletin. 50 (8): 1109–13. doi:10.1248/cpb.50.1109. PMID 12192147.
  3. ^ Zhang Y, Burgess JP, Brackeen M, Gilliam A, Mascarella SW, Page K, et al. (June 2008). "Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations". Journal of Medicinal Chemistry. 51 (12): 3526–39. doi:10.1021/jm8000778. PMID 18512901.
  4. ^ Tambaro S, Mongeau R, Dessi C, Pani L, Ruiu S (November 2005). "Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors". European Journal of Pharmacology. 525 (1–3): 150–3. doi:10.1016/j.ejphar.2005.09.058. PMID 16271359.


This page was last edited on 19 February 2024, at 15:26
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.